Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Dugan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Transfusion|December 2, 2008
Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilizationJames M Thompson, Pam Carlton, Luke P Akard, et al.
Journal of Cellular and Molecular Medicine|March 24, 2005
Transplantation of hematopoietic stem cells from the peripheral bloodJan Jansen, Susan Hanks, James M Thompson, et al.
American Journal of Hematology|December 21, 2004
Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplantMaureen A Cooper, Luke P Akard, James M Thompson, et al.
Journal of Oncology Practice|March 12, 2015
Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemiaStuart L Goldberg, Luke P Akard, Michael J Dugan, et al.
Postgraduate Medicine|July 21, 2016
Editor's MailMichael J Dugan, Myrtle Adamek, Brahm Lermer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2017
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or MaintainedLauren E Caldemeyer, Luke P Akard, John R Edwards, et al.
Transfusion|May 1, 2007
Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?Eva M Jansen, Susan G Hanks, Colin Terry, et al.
Mycoses|August 23, 2006
Delayed ABLC prophylaxis after allogeneic stem-cell transplantationJan Jansen, Luke P Akard, Matthew F Wack, et al.
Cytotherapy|January 21, 2009
Transportation of peripheral blood progenitor cell products: effects of time, temperature and cell concentrationJan Jansen, Pamela L Nolan, Margaret I Reeves, et al.
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis|March 12, 2002
Peripheral blood progenitor cell transplantationJan Jansen, James M Thompson, Michael J Dugan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Transfusion|December 2, 2008
Starting granulocyte-colony-stimulating factor (filgrastim) early after autologous peripheral blood progenitor cell transplantation leads to faster engraftment without increased resource utilizationJames M Thompson, Pam Carlton, Luke P Akard, et al.
Journal of Cellular and Molecular Medicine|March 24, 2005
Transplantation of hematopoietic stem cells from the peripheral bloodJan Jansen, Susan Hanks, James M Thompson, et al.
American Journal of Hematology|December 21, 2004
Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplantMaureen A Cooper, Luke P Akard, James M Thompson, et al.
Journal of Oncology Practice|March 12, 2015
Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemiaStuart L Goldberg, Luke P Akard, Michael J Dugan, et al.
Postgraduate Medicine|July 21, 2016
Editor's MailMichael J Dugan, Myrtle Adamek, Brahm Lermer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2017
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or MaintainedLauren E Caldemeyer, Luke P Akard, John R Edwards, et al.
Transfusion|May 1, 2007
Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?Eva M Jansen, Susan G Hanks, Colin Terry, et al.
Mycoses|August 23, 2006
Delayed ABLC prophylaxis after allogeneic stem-cell transplantationJan Jansen, Luke P Akard, Matthew F Wack, et al.
Cytotherapy|January 21, 2009
Transportation of peripheral blood progenitor cell products: effects of time, temperature and cell concentrationJan Jansen, Pamela L Nolan, Margaret I Reeves, et al.
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis|March 12, 2002
Peripheral blood progenitor cell transplantationJan Jansen, James M Thompson, Michael J Dugan, et al.
Pageof 2